Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Martin H. Cohen(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Mark D. Rothmann, Khin Maung U, John R. Johnson(Santa Barbara Museum of Natural History), Sung K. Kim, Jogarao Gobburu(University of Maryland, Baltimore), Ann Staten, Atiqur Rahman(Jamia Millia Islamia), Gang Chen(Fudan University), John K. Leighton, Kimberly Benson, John Duan, Rebecca Wood, Grant Williams
PubMed
May 1, 2002
Cited by 469
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k